Back to Forecasting
IBRX Forecast Markets
ImmunityBio, Inc.
6
Active Markets
55%
Avg Probability
All Markets
6 markets
Will IBRX Q2 2026 net product revenue exceed $45 million?
72%
Likely Yes
82% agreement
Aug 15, 2026
IG: 0.72
Will ImmunityBio announce a public equity or convertible debt offering by December 31, 2026?
85%
Likely Yes
88% agreement
Jan 15, 2027
IG: 0.68
Will ImmunityBio submit an sNDA/BLA for ANKTIVA in BCG-naive NMIBC to the FDA by December 31, 2026?
35%
Likely No
78% agreement
Jan 15, 2027
IG: 0.64
Will any conversion, restructuring, or extension of the $505M NantCapital convertible note be filed by December 31, 2026?
45%
Likely No
72% agreement
Jan 15, 2027
IG: 0.56
Will IBRX report cash and marketable securities below $150 million as of September 30, 2026?
55%
Likely Yes
76% agreement
Nov 15, 2026
IG: 0.56
Will the FDA provide a clear regulatory pathway (IND acceptance, sNDA, or accelerated approval discussion minutes) for ANKTIVA in NSCLC by December 31, 2026?
38%
Likely No
74% agreement
Jan 15, 2027
IG: 0.48
Resolution Timeline
Nov 15, 2026
Will IBRX report cash and marketable securities below $150 million as of September 30, 2026?Prediction: 55%
Jan 15, 2027
Will ImmunityBio announce a public equity or convertible debt offering by December 31, 2026?Prediction: 85%
Jan 15, 2027
Will ImmunityBio submit an sNDA/BLA for ANKTIVA in BCG-naive NMIBC to the FDA by December 31, 2026?Prediction: 35%